A Comparison of Sodium-Induced Responses by Sex

Sponsor
Texas State University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05815043
Collaborator
(none)
50
1
1
12.6
4

Study Details

Study Description

Brief Summary

The purpose of this study is to explore the influence of biological sex on sodium-induced blood pressure and vascular function responses to variations in sodium intake in African American/Black adults.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Low-sodium intake
  • Dietary Supplement: High-sodium intake
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Influence of Sex on Sodium-Induced Cardiovascular Responses in African American Adults
Actual Study Start Date :
Dec 13, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Low- and high-sodium intake

Participants will consume two different quantities of sodium per day for 3 days each.

Behavioral: Low-sodium intake
Participants will consume less than or equal to 720 milligrams of sodium per day for 3 days.

Dietary Supplement: High-sodium intake
Participants will supplement their existing diets with 10 salt tablets daily for 3 days.

Outcome Measures

Primary Outcome Measures

  1. Endothelial function [This measurement will take approximately 15 minutes and will be obtained from the date of enrollment until the date of completion of the study up to 10 days after enrollment.]

    Brachial artery flow-mediated dilation will be assessed after 15 minutes of supine rest.

  2. Ambulatory blood pressure [This measurement will take approximately 24 hours and will be obtained from the date of enrollment until the date of completion of the study up to 10 days after enrollment.]

    24-hour ambulatory blood pressure monitoring will be completed on day 3 of each dietary condition.

Secondary Outcome Measures

  1. Renal sodium excretion [This measurement will be obtained from the date of enrollment until the date of completion of the study up to 10 days after enrollment.]

    24-hour urine samples will be analyzed for sodium concentrations and sodium excretion will be determined.

Other Outcome Measures

  1. Hematocrit [This measurement will be obtained from the date of enrollment until the date of completion of the study up to 10 days after enrollment.]

    Hematocrit will be determined from whole blood samples after each 3-day dietary condition.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • African American or Black

  • Male or Female

Exclusion Criteria:
  • pregnancy or within 60 days postpartum

  • having taken blood pressure (including diuretics beta-blockers, ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers) or statin medications within the past 3 months

  • infection (viral or other) within the past 4 weeks

  • having adrenal or endocrine tumors (these could impact BP)

  • renal disease defined as a glomerular filtration rate (GFR) of less than 60

  • prior myocardial infarction

  • known coronary heart disease

  • personal history of stroke

  • heart failure

  • cardiac arrhythmias

  • recent chest pain or dyspnea

  • current insulin dependence

  • currently undergoing chemotherapy or radiation

  • identifying as transgender (the focus of this trial is biological sex)

  • seated systolic or diastolic blood pressure of more than 149 mm Hg or 99 mm Hg, respectively

Contacts and Locations

Locations

Site City State Country Postal Code
1 Texas State University San Marcos Texas United States 78666

Sponsors and Collaborators

  • Texas State University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Texas State University
ClinicalTrials.gov Identifier:
NCT05815043
Other Study ID Numbers:
  • 8663
First Posted:
Apr 18, 2023
Last Update Posted:
Apr 18, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Apr 18, 2023